Jacob Jørgensen

Mr. Jacob Jørgensen

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JJJacob Jørgensen
Jacob Jørgensen
MJMorten Leth Jepsen
Morten Leth Jepsen
LNLine Hagner Nielsen
Line Hagner Nielsen
MDMartin Dufva
Martin Dufva
HNHanne Morck Nielsen
Hanne Morck Nielsen
AMAnette Mullertz
Anette Mullertz

1 January 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
JJJacob Jørgensen
Jacob Jørgensen
LTLasse Højlund Eklund Thamdrup
Lasse Højlund Eklund Thamdrup
KKKhorshid Kamguyan
Khorshid Kamguyan
LNLine Hagner Nielsen
Line Hagner Nielsen
HNHanne Morck Nielsen
Hanne Morck Nielsen
AMAnette Mullertz
Anette Mullertz

7 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JJJacob Jørgensen
Jacob Jørgensen
FYFeiyang Yu
Feiyang Yu
RVRamakrishnan Venkatasubramanian
Ramakrishnan Venkatasubramanian
LNLine Hagner Nielsen
Line Hagner Nielsen
HNHanne Morck Nielsen
Hanne Morck Nielsen
AMAnette Mullertz
Anette Mullertz
Enhancing the oral bioavailability of peptides has received a lot of attention for decades but remains challenging, partly due to low intestinal membrane permeability. Combining a permeation enhancer (PE) with unidirectionally releasing microcontainers (MCs) has previously been shown to increase insulin permeation across Caco-2 cell monolayers. In the present work, this setup was further employed to compare three common PEs—sodium caprate (C10), sodium dodecyl sulfate (SDS), and lauroyl carnitine. The concept was also studied using porcine intestinal tissue with the inclusion of 70 kDa fluorescein isothiocyanate-dextran (FD70) as a pathogen marker. Moreover, a combined proteolysis and Caco-2 cell permeation setup was developed to investigate the effect of soybean trypsin inhibitor (STI) in the MCs. Lastly, in vivo performance of the MCs was tested in an oral gavage study in rats by monitoring blood glucose and insulin absorption. SDS proved to be the most potent PE without increasing the ex vivo uptake of FD70, while the implementation of STI further improved insulin permeation in the combined proteolysis Caco-2 cell setup. However, no insulin absorption in rats was observed upon oral gavage of MCs loaded with insulin, PE and STI. Post-mortem microscopic examination of their gastrointestinal tract indicated lack of intestinal retention and optimal orientation by the MCs, possibly precluding the potential advantage of unidirectional release.

2 April 2019 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
CMChiara Mazzoni
Chiara Mazzoni
RJRasmus Due Jacobsen
Rasmus Due Jacobsen
JMJacob Mortensen
Jacob Mortensen
JJJacob Jørgensen
Jacob Jørgensen
LVLukas Vaut
Lukas Vaut
ABAnja Boisen
Anja Boisen

1 June 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
HBHarriet Bennett-Lenane
Harriet Bennett-Lenane
JJJacob Jørgensen
Jacob Jørgensen
NKNiklas J. Koehl
Niklas J. Koehl
LHLaura J. Henze
Laura J. Henze
JOJoseph O’Shea
Joseph O’Shea
BGBrendan Griffin
Brendan Griffin
Validation and characterisation of in vitro and pre-clinical animal models to support bio-enabling formulation development is of paramount importance. In this work, post-mortem gastric and small intestinal fluids were collected in the fasted, fed state and at five sample-points post administration of a placebo Self-Emulsifying Drug Delivery System (SEDDS) in the fasted state to pigs. Cryo-TEM and Negative Stain-TEM were used for ultrastructure characterisation. Ex vivo solubility of fenofibrate was determined in the fasted-state, fed-state and post-SEDDS administration. Highest observed ex vivo drug solubility in intestinal fluids after SEDDS administration was used for optimising the biorelevant in vitro conditions to determine maximum solubility. Under microscopic evaluation, fasted, fed and SEDDS fluids resulted in different colloidal structures. Drug solubility appeared highest 1 hour post SEDDS administration, corresponding with presence of SEDDS lipid droplets. A 1:200 dispersion of SEDDS in biorelevant media matched the highest observed ex vivo solubility upon SEDDS administration. Overall, impacts of this study include increasing evidence for the pig preclinical model to mimic drug solubility in humans, observations that SEDDS administration may poorly mimic colloidal structures observed under fed state, while microscopic and solubility porcine assessments provided a framework for increasingly bio-predictive in vitro tools.

17 April 2025 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
MKMatthias Manne Knopp
Matthias Manne Knopp
JJJacob Jørgensen
Jacob Jørgensen
LHLaila Tognarelli Hansen
Laila Tognarelli Hansen
AMAnette Mullertz
Anette Mullertz
The pharmacokinetics (PK) of oral drug compounds are often significantly altered by food intake and evaluating this effect, as required by regulatory agencies, typically involves costly and time-consuming clinical trials. This study used the Dynamic Gastrointestinal Model (DGM), an advanced in vitro system simulating both biochemical and mechanical aspects of the human upper gastrointestinal tract, to predict plasma concentration-time profiles (PK profiles) and food effect of three immediate release oral drug products. The drug products, containing cinnarizine (CIN), diclofenac potassium (DIC) or paracetamol (PAR), were processed in the DGM mimicking the fasted and fed state clinical protocols and the resulting intestinal drug dissolution profiles were modelled (by convolution) to achieve the predicted PK profiles. The predicted PK profiles in both the fasted and fed state were in accordance with the observations in clinical trials, capturing both the positive food effect for CIN and the negative food effects for DIC and PAR. These findings demonstrate the ability of the DGM to provide insights into the PK performance and food effect of oral drug products.